Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • AML
      • Warm AIHA
      • COVID-19
      • IRAK1/4
      • RIPK1
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Sep 08, 2015 7:30am EDT

Rigel Granted Orphan Drug Designation for Fostamatinib in ITP

Aug 04, 2015 4:05pm EDT

Rigel Announces Second Quarter 2015 Financial Results

Jul 28, 2015 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results

Jun 30, 2015 7:30am EDT

Rigel Welcomes Keith A. Katkin to Board of Directors

May 28, 2015 7:30am EDT

Rigel to Present at Jefferies 2015 Global Healthcare Conference

May 07, 2015 4:05pm EDT

Rigel Announces First Quarter 2015 Financial Results

Mar 03, 2015 7:30am EST

Rigel Announces Fourth Quarter and Year End 2014 Financial Results

Feb 23, 2015 8:03am EST

Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

Jan 08, 2015 7:30am EST

Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Nov 24, 2014 7:30am EST

Rigel Announces Executive Management Changes

  • Previous
  • 1…
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • …34
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy

© 2022 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin